FINWIRES · TerminalLIVE
FINWIRES

Brookfield Asset Management in Good Position Heading Into Fundraising Cycle, RBC Says

By

Brookfield Asset Management (BAM) is well positioned heading into its fundraising cycle, with its private equity and infrastructure flagships, along with 60 fundraising strategies driving an estimated $150 billion in fundraising in 2026, RBC Capital Markets said Monday.

Brookfield's $3.5 billion of debt outstanding is below its US alternative asset management peers on key metrics including market cap, assets under management, and debt to fee-related earnings multiple, the brokerage said.

RBC sees Brookfield's rising debt as manageable and a good form of capital optimization over the long-term. However, the interest expense compresses distributable earnings growth in the near-term relative to fee-related earnings growth, and RBC estimates that the two metrics will converge in 2027, according to the note.

The private credit environment is turning more favorable for lenders, which should generate incremental fee opportunities for Brookfield Asset Management, the brokerage said.

RBC kept an outperform rating on Brookfield Asset Management and lowered the price target to $65 from $74.

Price: $49.36, Change: $-0.40, Percent Change: -0.80%

Related Articles

Australia

Truist Securities Lifts NETSTREIT Price Target to $22 From $21, Maintains Buy Rating

NETSTREIT (NTST) has an average rating of overweight and mean price target of $21.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $20.73, Change: $+0.06, Percent Change: +0.29%

$NTST
Australia

Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says

Gilead Sciences' (GILD) mid-stage trial results from its ulcerative colitis drug candidate, emvistegrast, are not expected to move the stock, RBC Capital Markets said in a note Monday.The outcome from the small molecule drug trial is expected shortly, the note said, adding that the competitive bar is high, and prior oral efforts have not looked great."Focus is likely to remain on Yeztugo/HIV/anito-cel nearterm, and a ph. II readout is unlikely to materially move the stock," the report said.The note said the drug candidate has some pharmacological advantages against others and favorable results could help its immunology and inflammation segment emerge as a potential new area of long-term growth generation.The report pointed to Eli Lilly's (LLY) recent EMERALD-2 phase 2b data that showed only modest efficacy.RBC kept its sector perform rating with a price target of $122.Price: $133.64, Change: $+2.31, Percent Change: +1.76%

$GILD
Australia

Argus Adjusts Price Target on Targa Resources to $290 From $270

Targa Resources (TRGP) has an average rating of overweight and mean price target of $271.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $254.86, Change: $+6.74, Percent Change: +2.72%

$TRGP